Phlebitis

Access Vascular Integrative Review Published in International Journal of Nursing and Healthcare Research Establishes Economic Impact of Biomaterial Catheters

Retrieved on: 
Monday, October 31, 2022
AVI, Hospital, Access, Water, Common, Thrombosis, CEO, Patient, Research, Infection, GLOBE, PICC, Catheter, FDA, Canadian International Council, Technology, Phlebitis, Innovation, Medical imaging, Nursing

BILLERICA, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Access Vascular, Inc. (AVI) , a company addressing the most common and costly vascular access complications through its advanced biomaterial platform, today shared key findings from an economic analysis published in the International Journal of Nursing and Research regarding AVIs consistently hydrophilic PICC and midline catheters.

Key Points: 
  • BILLERICA, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Access Vascular, Inc. (AVI) , a company addressing the most common and costly vascular access complications through its advanced biomaterial platform, today shared key findings from an economic analysis published in the International Journal of Nursing and Research regarding AVIs consistently hydrophilic PICC and midline catheters.
  • The analysis documents millions of dollars in available cost-savings for hospitals using biomaterial-based catheters to reduce vascular access complications.
  • This is a landmark finding for hospitals because it assigns a specific and significant cost-savings to a reduction in vascular access complications, said James Biggins, CEO of Access Vascular.
  • This changes the math, helping value analysis committees compute the true and total cost of new biomaterial-based vascular access catheter adoption.

Journal of Infusion Nursing Publishes Access Vascular Data Showing Significantly Reduced Complication Rates for HydroMID

Retrieved on: 
Monday, September 19, 2022
Workflow, Common, Journal, FDA, Thrombosis, Access, Data analysis, Phlebitis, Infection, Patient, CEO, Technology, Catheter, AVI, Ascending limb of loop of Henle, Water, RN, GLOBE, Infusion, Hospital, Venous thrombosis, Failure, Innovation, Medical imaging

In the paper, A Retrospective Assessment of Midline Catheter Failures Focusing on Catheter Composition, complication rates are compared in 101 standard midline catheters and 104 HydroMID catheters.

Key Points: 
  • In the paper, A Retrospective Assessment of Midline Catheter Failures Focusing on Catheter Composition, complication rates are compared in 101 standard midline catheters and 104 HydroMID catheters.
  • The data analysis indicates statistically significant reductions in failure rates, upper extremity deep venous thrombosis, and phlebitis in the HydroMID group, with the polyurethane midline catheters six (6) times more likely to fail then HydroMID catheters.
  • To learn more about Access Vascular and its HydroPICC and HydroMID products, please visit www.accessvascularinc.com .
  • Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis.

COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Retrieved on: 
Wednesday, July 13, 2022
Regulation of tobacco by the U.S. Food and Drug Administration, Thrombophlebitis, Marketing, Hypophosphatemia, Incidence, Hypokalemia, Bladder cancer, G1 Therapeutics, Therapy, Lung, National Medical Products Administration, G1, Trilaciclib, History, Pneumonitis, Headache, NMPA, Hypocalcemia, Aplastic anemia, Patient, Pneumonia, Adult, Food, GLOBE, RESEARCH, Colorectal cancer, U.S. Securities and Exchange Commission, Breast, Risk, Private Securities Litigation Reform Act, Nasdaq, Phlebitis, Forward-looking statement, Fatigue, FDA, PARK, Simcere Pharmaceutical, Research Triangle Park, Cancer, Interstitial lung disease, Pharmaceutical industry, Vaccine

COSELA is now indicated in China to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer.

Key Points: 
  • COSELA is now indicated in China to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer.
  • G1 may also receive double-digit royalties on annual net sales of COSELA in China.
  • It is predicted that, by 2040, the number of new cancer patients requiring chemotherapy in China will reach 4.2 million.
  • COSELA (trilaciclib) is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer.

New Access Vascular Retrospective Data Review Demonstrates Midline Catheters Composed of Advanced Biomaterials May Improve Dwell Times

Retrieved on: 
Tuesday, July 12, 2022
Deep vein thrombosis, DVT, Catheter, Incidence, Infection, Thrombosis, GLOBE, AVI, Trust, Occlusion, Phlebitis, FDA, Water, Medical imaging

This new data shows that choosing the right catheter can make all the difference, giving clinicians the trust and competence they desire from their vascular access devices.

Key Points: 
  • This new data shows that choosing the right catheter can make all the difference, giving clinicians the trust and competence they desire from their vascular access devices.
  • We are confident that new, ongoing studies will demonstrate even longer dwell times for AVIs biomaterial-based catheters.
  • AVIs patented hydrophilic biomaterial catheters mimic the bodys chemistry to significantly reduce the most common and costly complications associated with vascular access procedures.
  • Given the high utilization and complication rates of standard catheters, the use of AVI devices may meaningfully improve patient outcomes.

Access Vascular Inc. Named 2022 MedTech Breakthrough Award Winner

Retrieved on: 
Tuesday, May 10, 2022
Water, GLOBE, Medicine, DVT, Patient, Infection, FDA, AVI, Hospital, Catheter, Phlebitis, Thrombosis, Health, Deep vein thrombosis, Medtech, CEO, Pharmaceutical industry, Medical imaging

BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Access Vascular, Inc. (AVI ) today announced it has been named Best New Technology Solution Drug Delivery in the 2022 MedTech Breakthrough Awards.

Key Points: 
  • BILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Access Vascular, Inc. (AVI ) today announced it has been named Best New Technology Solution Drug Delivery in the 2022 MedTech Breakthrough Awards.
  • AVIs patented, groundbreaking new biomaterial-based catheters were recognized for their potential to reshape the field of vascular access and value based care at large.
  • The majority of hospitalized patients receive a vascular access device, and more than 30% of those will experience some type of complication, including thrombus or infection.
  • Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis.

Access Vascular Receives FDA Clearance for HydroPICC® Biomaterial-Based Dual-Lumen Catheter

Retrieved on: 
Thursday, May 5, 2022
PICC, Water, GLOBE, Thrombus, Food and Drug Administration, Food, Patient, Infection, FDA, Family, AVI, Hospital, Catheter, Phlebitis, Thrombosis, Deep vein thrombosis, AVA, TPA, Risk, Medical imaging

BILLERICA, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Access Vascular, Inc. (AVI) today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its HydroPICC Dual-Lumen catheter.

Key Points: 
  • BILLERICA, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Access Vascular, Inc. (AVI) today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its HydroPICC Dual-Lumen catheter.
  • We are proud to announce FDA clearance for our HydroPICC Dual-Lumen catheter as the latest addition to our family of devices, said Access Vascular CEO James Biggins.
  • Hospital patients experience unnecessarily high incidences of vascular access complications, largely because of the material used by competitive catheters.
  • A majority of hospital patients receive a vascular access device and 30% of those patients encounter a vascular access-related complication.

Access Vascular Inc. Wins 2022 Edison Award for Innovation

Retrieved on: 
Tuesday, April 26, 2022
Water, CEO, Phlebitis, Edison Awards, Workflow, Marketing, AVI, Catheter, Science, Edison Award, Leadership, Hospital, Deep vein thrombosis, GLOBE, DVT, Patient, Infection, Gold Award, Safety, Thrombosis, FDA, Time, Pharmaceutical industry, Medical imaging

BILLERICA, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Access Vascular, Inc. (AVI ) today announced its biomaterial-based hydrophilic catheters received a Gold Award as the 2022 Edison Best New Product in science and medical at the 2022 Edison Awards.

Key Points: 
  • BILLERICA, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Access Vascular, Inc. (AVI ) today announced its biomaterial-based hydrophilic catheters received a Gold Award as the 2022 Edison Best New Product in science and medical at the 2022 Edison Awards.
  • The Edison Awards is an annual honor designed to recognize excellence in new product and service development, marketing, human-centered design and innovation.
  • Edison Award recipients represent game changing products, services, excellence and leadership in innovation around four criteria: Concept, Value, Delivery and Impact.
  • We are proud to join the impressive list of innovative companies named as past and present Edison Award winners, said James Biggins, CEO at Access Vascular, Inc.

Access Vascular, Inc. Opens New Facility Outside Boston With Expanded Production Capacity to Meet Growing Demand for Its Biomaterial Devices

Retrieved on: 
Monday, March 28, 2022
Â, Phlebitis, GLOBE, CEO, Research, Technology, AVI, FDA, Thrombosis, Water, Patient, Infection, Medical imaging

The new, enhanced facility is equipped with an expanded manufacturing line, increased lab space and a larger clean room.

Key Points: 
  • The new, enhanced facility is equipped with an expanded manufacturing line, increased lab space and a larger clean room.
  • It will support the accelerated commercialization of AVIs technology, while also providing necessary space for ongoing research and development projects involving its patented biomaterials.
  • This transformational technology was most recently recognized as a Big Innovation Award Winner for its potential to reshape the field of vascular access.
  • Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis.

Access Vascular Inc. Partners with Healthcare Insights to Develop New MedTech Value-Based Care Program

Retrieved on: 
Thursday, February 10, 2022
GLOBE, Phlebitis, AVI, Infection, Program, FDA, Hospital, Catheter, Deep vein thrombosis, Health, CEO, Medtech, Water, Partnership, Thrombosis, HCIS, DVT, Medical imaging

BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Access Vascular, Inc. (AVI ), today announced its partnership with Healthcare Insights (HCIS) to build a value-based care program that can more broadly support hospital customers as they deploy the companys groundbreaking biomaterial-based catheters to improve vascular access medical and economic outcomes.

Key Points: 
  • BILLERICA, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Access Vascular, Inc. (AVI ), today announced its partnership with Healthcare Insights (HCIS) to build a value-based care program that can more broadly support hospital customers as they deploy the companys groundbreaking biomaterial-based catheters to improve vascular access medical and economic outcomes.
  • AVI is leveraging decades of hospital administration, clinical and reimbursement expertise from HCIS in the development of its outcome-based care program for hospitals in the United States.
  • The program focuses on helping acute care facilities reduce practice variation and standardize procedural practice for improved outcomes and reduced costs associated wth vascular access complications such as thrombosis, infections, replacments and readmissions.
  • Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis.

Access Vascular Inc. Named 2022 BIG Innovation Award Winner

Retrieved on: 
Tuesday, January 11, 2022
Medicine, Patient, Phlebitis, Medtech, Catheter, DVT, Knowledge, CEO, GLOBE, Organization, Deep vein thrombosis, Time, Thrombosis, Water, Infection, FDA, AVI, Life, Medical imaging, Risk management

BEDFORD, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Access Vascular, Inc. (AVI ), a company addressing the most common and costly vascular access complications, today announced it has been named a winner in the 2022 BIG Innovation Awards presented by the Business Intelligence Group.

Key Points: 
  • BEDFORD, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Access Vascular, Inc. (AVI ), a company addressing the most common and costly vascular access complications, today announced it has been named a winner in the 2022 BIG Innovation Awards presented by the Business Intelligence Group.
  • This transformational technology has the potential to reshape the field of vascular access and value based care at large.
  • The BIG Innovation Awards recognize organizations, products, and people that are bringing new ideas to life in innovative ways.
  • Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis.